[1]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798-801.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
　CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(8):798-801.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
点击复制

P2Y12抑制剂与癌症风险的相关性研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年8期
页码:
798-801
栏目:
综述
出版日期:
2020-08-25

文章信息/Info

Title:
Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk
作者:
陈凯磊1 胡闻竹1 苏冠华2
(1.华中科技大学同济医学院第一临床学院,湖北 武汉 430022;2.华中科技大学同济医学院附属协和医院心血管内科,湖北 武汉 430022)
Author(s):
CHEN Kailei1;  HU Wenzhu1;  SU Guanhua2
(1. First Clinical School, Tongji Medical College , Huazhong University of Science and Technology , Wuhan 430022, Hubei, China; 2. Department of Cardiology , Union Hospital , Tongji Medical College , Huazhong University of Science and Technology , Wuhan 430022, Hubei, China)
关键词:
P2Y12抑制剂; 氯吡格雷; 替格瑞洛; 癌症; 急性冠脉综合征
Keywords:
P2Y12 inhibitor;  Clopidogrel;  Ticagrelor;  Cancer;  Acute coronary syndrome
DOI:
10.16806/j.cnki.issn.1004-3934.2020.08.004
摘要:
以氯吡格雷、替格瑞洛为代表的P2Y12抑制剂目前被广泛应用于心脑血管疾病的抗血小板治疗，而血小板功能的变化可能影响肿瘤的发生发展，因此P2Y12抑制剂的应用与癌症发生风险的相关性备受关注。目前的证据显示应用P2Y12抑制剂总体安全，一般不会升高患者的癌症风险，相反甚至可能降低癌症发生率。基础研究表明，P2Y12抑制剂可能通过影响血小板功能、上皮细胞-间充质转化、炎症免疫因子、肿瘤内血管新生以及血小板-肿瘤细胞相互作用等多种机制抑制肿瘤细胞的增殖和迁移。
Abstract:
P2Y12 inhibitors, such as clopidogrel and ticagrelor, are widely used in antiplatelet therapy for cardiovascular and cerebrovascular diseases, and the changes of platelet function may affect the development and progression of tumor, so the correlation between P2Y12 inhibitors and cancer risk has attracted much attention. According to the literature review, current evidence shows that P2Y12 inhibitors are generally safe, without increasing the risk of cancer . On the contrary, they may even reduce the incidence of cancer. Basic researches show that P2Y12 inhibitor s may inhibit the proliferation and migration of tumor cells by influencing platelet function, epithelial-mesenchymal trans ition, inflammatory and immunoregulatory factors, tumor angiogenesis and platelet-tumor cell interaction.

参考文献/References:


[1]Ballerini P,Dovizio M,Bruno A,et al.P2Y12 receptors in tumorigenesis and metastasis[J].Front Pharmacol,2018,9:1-8.

[2]闫伟国,杨树森.围术期新型抗血小板及抗凝药物管理[J].心血管病学进展,2018,39(5):776-780.

[3]Serebruany VL,Cherepanov V,Cabrera-Fuentes HA,et al.Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges[J].Thromb Haemost,2015,114(6):1104-1112.

[4]Kotronias R,Kwok C,Wong C,et al.Cancer event rate and mortality with thienopyridines:a systematic review and meta-analysis[J].Drug Saf,2017,40(3):229-240.

[5]Kaufmann C,Lyon A,Wojta J,et al.Is P2Y12 inhibitor therapy associated with an increased risk of cancer?[J].Eur Heart J Cardiovasc Pharmacother,2019,5(2):100-104.

[6]Fierro J,Cave B,Khouzam R.P2Y12 inhibitors: do they increase cancer risk?[J].Ann Transl Med,2019,7(17):409.

[7]Leader A,Zelikson-Saporta R,Pereg D,et al.The effect of combined aspirin and clopidogrel treatment on cancer incidence[J].Am J Med,2017,130(7):826-832.

[8]Rodríguez-Miguel A,García-Rodríguez L,Gil M,et al.Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer[J].Clin Gastroenterol Hepatol,2019,17(10):2024-2033.

[9]Kuan Y,Huang K,Lin C,et al.Effects of aspirin or clopidogrel on colorectal cancer chemoprevention in patients with type 2 diabetes mellitus[J].Cancers (Basel),2019,11(10):1468-1483.

[10]Elmariah S,Doros G,Benavente O,et al.Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease:a patient-level meta-analysis[J].Circ Cardiovasc Interv,2018,11(1):005795.

[11]Serebruany V,Kim M,Cabrera-Fuentes H,et al.Mortality and cancer after 12 versus 30 months dual antiplatelet therapy: The Korean outcomes registry evaluating antithrombotics(Korea)[J].Thromb Haemost,2017,117(5):934-939.

[12]Mauri L,Elmariah S,Yeh R,et al.Causes of late mortality with dual antiplatelet therapy after coronary stents[J].Eur Heart J,2016,37(4):378-385.

[13]Wiviott S,Braunwald E,McCabe C,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.

[14]Raposeiras-Roubín S,Abu-Assi E,Mu?oz-Pousa I,et al.Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor[J].Thromb Res,2019,174:51-58.

[15]Stegner D,Dütting S,Nieswandt B.Mechanistic explanation for platelet contribution to cancer metastasis[J].Thromb Res,2014,133(suppl 2):S149-S157.

[16]Xu X,Yousef G,Ni H.Cancer and platelet crosstalk:opportunities and challenges of aspirin and other antiplatelet agents[J].Blood,2018,131(16):1777-1789.

[17]Patrignani P,Patrono C.Aspirin and cancer[J].J Am Coll Cardiol,2016,68(9):967-976.

[18]Kopp H,Placke T,Salih H.Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity[J].Cancer Res,2009,69(19):7775-7783.

[19]Viel S,Mar?ais A,Guimaraes F,et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway[J].Sci Signal,2016,9(415):1-14.

[20]Timar J,Tovari J,Raso E,et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance[J].Oncology,2005,69(3):185-201.

[21]Labelle M,Begum S,Hynes R.Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis[J].Cancer Cell,2011,20(5):576-590.

[22]Janowska-Wieczorek A,Wysoczynski M,Kijowski J,et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer[J].Int J Cancer,2005,113(5):752-760.

[23]Lonsdorf A,Kramer B,Fahrleitner M,et al. Engagement of αⅡbβ3 (GPⅡb/Ⅲa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis[J].J Biol Chem,2012,287(3):2168-2178.

[24] Gebremeskel S,LeVatte T,Liwski R,et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer[J].Int J Cancer,2015,136(1):234-240.

[25]Li N.Platelets in cancer metastasis: to help the "villain" to do evil[J].Int J Cancer,2016,138(9):2078-2087.

[26]Jovani M,Chan A. Do Aspirin and clopidogrel follow the same road toward prevention of colorectal cancer?[J].Clin Gastroenterol H,2019,17(10):1945-1947.

[27]Ho-Tin-Noé B,Goerge T,Cifuni S,et al. Platelet granule secretion continuously prevents intratumor hemorrhage[J].Cancer Res,2008,68(16):6851-6858.

[28]Bambace N,Levis J,Holmes C.The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets[J].Platelets,2010,21(2):85-93.

[29]Mezouar S,Darbousset R,Dignat-George F,et al.Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo[J].Int J Cancer,2015,136(2):462-475.

[30]Thiery J,Acloque H,Huang R,et al.Epithelial-mesenchymal transitions in development and disease[J].Cell,2009,139(5):871-890.

[31]Guillem-Llobat P,Dovizio M,Bruno A,et al.Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells[J].Oncotarget,2016,7(22):32462-32477.

[32]Nasti T,Bullard D,Yusuf N.P-selectin enhances growth and metastasis of mouse mammary tumors by promoting regulatory T cell infiltration into the tumors[J].Life Sci,2015,131:11-18.

[33]Zeng L,O’Connor C,Zhang J,et al.IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines[J].Cytokine,2010,49(3):294-302.

[34]Gareau A,Brien C,Gebremeskel S,et al.Ticagrelor inhibits platelet–tumor cell interactions and metastasis in human and murine breast cancer[J].Clin Exp Metastasis,2018,35(1-2):25-35.

[35]Sitia G,Aiolfi R,di Lucia P,et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B[J].Proc Natl Acad Sci U S A,2012,109(32):E2165-E2172.

[36]Brott D,Andersson H,Stewart J,et al. A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance:mode of action consistent with dopamine agonism[J].Toxicol Rep,2014,1:1202-1212.

[37]Buckley L,Sanbuissho A,Starling J,et al. Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent[J].Int J Toxicol,2012,31(4):317-325.

相似文献/References:

[1]朱佩,袁晋青.P2Y12受体拮抗剂与质子泵抑制剂相互作用的研究进展[J].心血管病学进展,2015,(5):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
　ZHU Pei,YUAN Jinqing.Review of Interactions Between P2Y12 Receptor Antagonists and Proton Pump Inhibitors[J].Advances in Cardiovascular Diseases,2015,(8):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
[2]袁德山,袁晋青.冠心病患者中基于基因检测的个体化抗血小板治疗最新研究进展[J].心血管病学进展,2019,(6):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
　YUAN Deshan,YUAN Jinqing.Individualized Antiplatelet Therapy Based on Gene Testing in Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(8):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
[3]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
　ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(8):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
　WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(8):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]

备注/Memo

备注/Memo:

 基金项目：国家自然科学基金（81700345）
通讯作者：苏冠华，E-mail：suguanhua@163.com
收稿日期：2020-02-21

更新日期/Last Update: 2020-11-02